Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. Issue 2 (23rd October 2021)

• Record Type: Journal Article
• Authors: Groot, Jonathan; Petersen, Tanja G; Suren, Pål; Brantsæter, Anne Lise; Uldall, Peter; Martinussen, Torben; Granström, Charlotta; Olsen, Sjurdur F; Wilcox, Allen J; Strandberg-Larsen, Katrine
• Is Part Of: American journal of clinical nutrition. Volume 115:Issue 2(2022)
• Page Start: 397
• Page End: 406
• Publication Date: 2021-10-23
• Subjects: DNBC -- MoBa -- MOBAND-CP -- cerebral palsy -- folic acid -- nutrition -- epidemiology -- neurodevelopment -- food frequency questionnaire; Diet therapy -- Periodicals; Nutrition -- Periodicals; Dietetics -- Periodicals; 613.205
• DOI: 10.1093/ajcn/nqab351
• Languages: English
• ISSNs: 0002-9165

Abstract

ABSTRACT: Background: Folate prevents neural tube defects and may play a role in some neurodevelopmental disorders. Objectives: We investigated whether higher intakes of periconceptional or midpregnancy folate, as recommended, were associated with a reduced risk of offspring cerebral palsy (CP). Methods: We included participants from the Nordic collaboration cohort consisting of mother-child dyads in the Danish National Birth Cohort and the Norwegian Mother, Father, and Child Cohort Study [combined as MOthers and BAbies in Norway and Denmark (MOBAND-CP)]. A total of 190, 989 live-born children surviving the first year of life were included. Missing covariate data were multiply imputed. Our exposures were defined as any or no folic acid supplementation in gestational weeks (GWs) –4 to 8 (periconceptional), 9 to 12, and –4 to 12, and supplemental, dietary, and total folate during midpregnancy (GWs 22–25). CP overall and the unilateral and bilateral spastic subtypes, as well as CP with low or moderate/high gross motor function impairments, were our outcomes of interest. Results: Periconceptional folic acid supplementation was not associated with CP [adjusted odds ratio (aOR), 1.02; 95% CI: 0.82–1.28]. However, supplementation in GWs 9 to 12 was associated with a reduced risk of CP (aOR, 0.74; 95% CI: 0.57–0.96), and inverse associations were indicated for both the unilateral (aOR, 0.68; 95% CI: 0.46–1.02) and bilateral (aOR, 0.70; 95% CI: 0.49–1.02) spastic subtypes, although the associations were not statistically significant. Supplemental or dietary folate in midpregnancy alone were not associated with CP. Strong inverse associations were observed with low gross motor function impairment (aOR, 0.49; 95% CI: 0.29–0.83), while for unilateral CP the aOR was 0.63 (95% CI: 0.34–1.22) for intakes of ≥500 compared to ≤199 dietary folate equivalents/day during midpregnancy. Conclusions: Our findings suggest that folate intakes in GWs 9 to 12 and midpregnancy were associated with lower risks of CP, while no association was observed for periconceptional supplementation.